Ziihera Meets Overall Survival Endpoint at HERIZON-GEA-01 Second Interim, Completing the Phase 3 Win

BeOne Medicines and Jazz Pharmaceuticals said Monday that the second interim analysis of the Phase 3 HERIZON-GEA-01 trial met the overall survival co-primary endpoint for Ziihera (zanidatamab-hrii) plus chemotherapy in first-line HER2-positive gastroesophageal adenocarcinoma, completing the study’s dual primary endpoints six days after U.S. regulators cleared the regimen.

At the second interim analysis, Ziihera plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in overall survival versus trastuzumab plus chemotherapy. It is the first time the doublet has crossed the significance threshold on survival; at the first interim readout in November 2025, that arm showed only a strong trend toward significance.

Longer follow-up on the triplet arm, Tevimbra (tislelizumab) plus Ziihera and chemotherapy, showed an improved overall survival hazard ratio and durable outcomes. The safety profile was consistent with the first interim analysis and the known profiles of each agent, with no new safety signals.

The readout comes days after the FDA on Aug. 25 approved supplemental Biologics License Applications for both Ziihera and Tevimbra in combination with chemotherapy for first-line HER2+ gastric, gastroesophageal junction, or esophageal adenocarcinoma. That decision, based on the first interim analysis published in the New England Journal of Medicine, made the triplet the first immunotherapy-based regimen in the setting to show median overall survival exceeding two years regardless of PD-L1 status.

HERIZON-GEA-01 randomized 914 patients across roughly 300 sites in more than 30 countries, comparing Ziihera plus chemotherapy with and without Tevimbra against trastuzumab plus chemotherapy on dual primary endpoints of progression-free survival by blinded independent central review and overall survival.

The survival readout is especially meaningful for BeOne, which holds Ziihera rights across much of Asia, excluding India and Japan, where the burden of gastroesophageal cancer is high. Jazz holds rights in all other regions, and the two companies develop zanidatamab under license from Zymeworks.

BeOne shares closed Friday at $366.73; Jazz closed at $244.54. The second interim analysis results have been submitted for presentation at a major medical meeting in the fourth quarter.

For the approval, label, and trial details, see our coverage of the Aug. 25 first-line approval. The full press release is available from BeOne Medicines.

What It Means for the Trade

The sequencing here is unusual and worth flagging: full survival confirmation arrived six days after the approval, not before it. The FDA approved on the first-interim data (PFS co-primary met, OS trending), which means the label already in physicians’ hands is now backed by a completed dual-primary win rather than an IOU. That materially upgrades the durability of the franchise — no accelerated-approval confirmatory overhang, no scenario where a maturing OS curve walks back the launch. For a specialty pharma like Jazz, that removes the single most common post-approval derating trigger.

For the trade specifically, read the two arms correctly. The doublet (Ziihera + chemo) crossing its OS significance threshold is the cleaner story — it’s the arm with the IHC 3+ label, the simpler regimen, and now a statistically hard survival win versus the trastuzumab incumbent. The triplet’s “improved hazard ratio with durable outcomes” language is softer, and the Q4 congress presentation is where the market will find out whether the triplet’s final OS number lands clearly superior to the doublet or merely comparable. That comparison determines regimen mix: if the triplet’s advantage is marginal, the PD-L1-unselected triplet label competes against its own simpler doublet, and payers will push the cheaper option.

BeOne holders got the more direct read. The stock at $366.73 reflects a company mid-transformation from “BeiGene” to a global oncology platform, and zanidatamab’s Asian rights sit squarely in the highest-burden gastroesophageal cancer geography on earth — China alone accounts for roughly half of global gastric cancer cases. A completed survival dataset supports China market share defense and expansion into the rest of its Asian territory, complementing the Tevimbra (tislelizumab) franchise that anchors BeOne’s immuno-oncology business.

Trial Context: How to Read a Second Interim

Some mechanics for parsing the presentation when it lands. HERIZON-GEA-01’s dual primaries were PFS by blinded independent central review and OS; the first interim (November 2025, NEJM) cleared PFS decisively (35% risk reduction, 12.4 vs 8.1 months median) and showed the triplet’s OS at 26.4 vs 19.2 months (HR 0.72, 28% risk reduction) while the doublet showed a “strong trend” short of the significance bar. This second interim is the doublet’s OS formally crossing, with longer triplet follow-up improving its hazard ratio — the pattern you want to see, because it means both curves are still separating rather than converging with maturity.

What to scrutinize in the full slides: the doublet’s final hazard ratio and whether median OS is reached; subgroup performance by HER2 IHC/ISH stratum, PD-L1 status, and primary tumor site (gastric vs GEJ vs esophageal adenocarcinoma — esophageal response patterns often differ); and updated safety, particularly the diarrhea and infusion-reaction burden that drives real-world discontinuation. Also watch the PFS2 or subsequent-therapy data if disclosed — post-progression treatment patterns determine how much of the OS gain survives crossover arguments.

Risks and What Could Go Wrong

The completed Phase 3 removes clinical-trial risk but not commercial or competitive risk. Enhertu’s owners (AstraZeneca/Daiichi Sankyo) have first-line HER2+ GEA ambitions of their own, and an ADC beating a bispecific head-to-head in that future trial would compress zanidatamab’s window as the unchallenged standard. On the BeOne side, Tevimbra’s role inside the triplet means its commercial story is now partially entangled with zanidatamab’s — if regimen mix shifts toward the doublet (IHC 3+ patients foregoing the PD-1), BeOne captures less of the value than the headline suggests. And for both companies, China’s zanidatamab economics run through competitive tendering dynamics where domestic HER2-targeted agents are proliferating.

The last risk is interpretive: “improved hazard ratio” without a number invites both bull and bear spin until the Q4 presentation. Stocks that rally on topline adjectives sometimes give it back on detailed slides if the improvement is from HR 0.80 to 0.75 rather than 0.80 to 0.65. Hold judgment until the curves are public, and watch the Q4 congress calendar — a late-breaker slot at ESMO or ASCO GI is where this lands.